About this deal
Dollerup, O. L. et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am. J. Clin. Nutr. 108, 343–353 (2018).
Nemoto, S., Fergusson, M. M. & Finkel, T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1α. J. Biol. Chem. 280, 16456–16460 (2005). Liau, B.B.; Sievers, C.; Donohue, L.K.; Gillespie, S.M.; Flavahan, W.A.; Miller, T.E.; Venteicher, A.S.; Hebert, C.H.; Carey, C.D.; Rodig, S.J.; et al. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. Cell Stem Cell 2017, 20, 233–246.e7. [ Google Scholar] [ CrossRef] [ PubMed][ Green Version] Virág, L., Jaén, R. I., Regdon, Z., Boscá, L. & Prieto, P. Self-defense of macrophages against oxidative injury: fighting for their own survival. Redox Biol. 26, 101261 (2019). Stromsdorfer, K. L. et al. NAMPT-mediated NAD + biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep. 16, 1851–1860 (2016). An impaired response to exogenous or endogenous insulin to increase glucose uptake and utilization, resulting in elevated levels of glucose in the blood. Xeroderma pigmentosum
Osborne, B.; Bentley, N.L.; Montgomery, M.K.; Turner, N. The role of mitochondrial sirtuins in health and disease. Free Radic. Biol. Med. 2016, 100, 164–174. [ Google Scholar] [ CrossRef] [ PubMed] Bai, P. et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 13, 461–468 (2011).
Zhao, Z. Y. et al. A cell-permeant mimetic of NMN activates SARM1 to produce cyclic ADP-ribose and induce non-apoptotic cell death. iScience 15, 452–466 (2019). Xie, N.; Zhang, L.; Gao, W.; Huang, C.; Huber, P.E.; Zhou, X.; Li, C.; Shen, G.; Zou, B. NAD+ metabolism: Pathophysiologic mechanisms and therapeutic potential. Signal Transduct. Target. Ther. 2020, 5, 227. [ Google Scholar] [ CrossRef] Deaglio, S. et al. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol. Med. 16, 87–91 (2010). Gardell, S. J. et al. Boosting NAD with a small molecule that activates NAMPT. Nat. Commun. 10, 3241 (2019). Deaglio, S. et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J. Immunol. 160, 395–402 (1998).Lee, K.-A. et al. Characterization of age-associated exhausted CD8 + T cells defined by increased expression of Tim-3 and PD-1. Aging Cell 15, 291–300 (2016). Dong, P.; Karaayvaz, M.; Jia, N.; Kaneuchi, M.; Hamada, J.; Watari, H.; Sudo, S.; Ju, J.; Sakuragi, N. Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis. Oncogene 2012, 32, 3286–3295. [ Google Scholar] [ CrossRef][ Green Version] Mitchell, S. J. et al. Nicotinamide improves aspects of healthspan, but not lifespan, in mice. Cell Metab. 27, 667–676.e4 (2018). Cambronne, X. A. et al. Biosensor reveals multiple sources for mitochondrial NAD +. Science 352, 1474–1477 (2016). Stefano, M. D. et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. Cell Death Differ. 22, 731–742 (2015).
Jang, S.-Y., Kang, H. T. & Hwang, E. S. Nicotinamide-induced mitophagy: event mediated by high NAD +/NADH ratio and SIRT1 protein activation. J. Biol. Chem. 287, 19304–19314 (2012). Pathria, P., Louis, T. L. & Varner, J. A. Targeting tumor-associated macrophages in cancer. Trends Immunol. 40, 310–327 (2019). Yoshino, J., Baur, J. A. & Imai, S.-I. NAD intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 27, 513–528 (2018).Long, A. N. et al. Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine model. BMC Neurol. 15, 19 (2015). Shibue, T.; Weinberg, R.A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 2017, 14, 611–629. [ Google Scholar] [ CrossRef][ Green Version] Lee, C. F. et al. Normalization of NAD + redox balance as a therapy for heart failure. Circulation 134, 883–894 (2016).